Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review

@article{Elkjaer2020EvidenceAI,
  title={Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review},
  author={Anna Sofie Elkjaer and Sidsel Kirstine Lynge and Jakob Grauslund},
  journal={Acta Ophthalmologica},
  year={2020},
  volume={98}
}
Eye screening is mandatory in diabetes, but treatment is only indicated at the sight‐threatening stages of diabetic retinopathy (DR). Treatments include intravitreal injections, laser photocoagulation and vitrectomy, which are all invasive options. In order to prevent or delay DR, it is important to investigate earlier, non‐invasive managements prior to sight‐threatening DR. The aim of this study is to evaluate the effect of systemic treatment on incident and progressive DR. The search in this… 

Nanomedicine for Treating Diabetic Retinopathy Vascular Degeneration

Current advances in generating nanomedicine for diabetic retinopathy are described, focusing on the properties of the different materials tested explicitly for this purpose, and some materials showed a natural ability to mitigate pathological neo-angiogenesis.

Type 2 diabetes patient’s awareness and KAP regarding diabetic retinopathy: Cross-sectional multinational study from the middle east

The study sheds light the importance of improving the patients' awareness and KAP regarding to DM and prevention of DR and recommends large multi-center multinational studies in the Middle East region to confirm the study inferences.

Experience of patients with diabetic retinopathy: A qualitative study.

This study helps assist medical staff in the early management of patients with DR and provides a reference for the construction of prevention programs for patients.

Unveiling the Nanotechnology-Based Drug Delivery Systems and Patent Literature for Diabetic Retinopathy

Nanotechnology-based formulations like nanoparticles, polymeric nanomicelles, and nanocarrier composite, and various patented formulations have been investigated for the treatment of DR.

The Role of Inflammation in Diabetic Retinopathy

The relationship between early leukocytes activation and the later features of DR are discussed, common pathogenetic processes between diabetic microvascular disease and other vascular retinopathies, the mechanisms whereby leukocyte activation is induced in hyperglycemia and dyslipidemia, the signaling mechanisms involved in diabetic microVascular disease, and possible interventions which may prevent these retInopathies.

The effect of educational program based on theory of planned behavior on promoting retinopathy preventive behaviors in patients with type 2 diabetes: RCT

Applying the TPB model proved is very effective in developing an educational program for patients with diabetes, to control their blood sugar and enhance preventive behaviors of retinopathy.

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome–Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice

Fenofibrate potently attenuated LG inflammation in a model of autoimmune dry eye, and this effect might partially result from regulating Th1/Th17/Treg cell responses by activating PPAR-α/LXR-β signaling.

References

SHOWING 1-10 OF 25 REFERENCES

The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.

There is firm evidence that fenofibrate slows the progression of diabetic Retinopathy and the need for more invasive treatment modalities in patients with type 2 diabetes, especially those with pre-existing retinopathy.

Diabetic Retinopathy and Other Ocular Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Intensive treatment delays the onset and slows the progression of DR, and the early effects of metabolic control continue to accrue over many years despite subsequent comparable glycemic control (metabolic memory).

Global Prevalence and Major Risk Factors of Diabetic Retinopathy

Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR, and these data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence.

Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society)

Screening procedures of DR, new technologies in the early diagnosis ofDR, control of risk factors in the different stages of the disease, indications of panretinal laser photocoagulation, efficacy of intravitreal antiangiogenic agents and steroids, and surgical options for treating DR-related complications are presented.

Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies

Fenofibrate is effective in preventing progression of established diabetic Retinopathy in type 2 diabetes and should be considered for patients with pre-proliferative diabetic retinopathy and/or diabetic maculopathy, particularly in those with macular oedema requiring laser.

Effects of medical therapies on retinopathy progression in type 2 diabetes.

Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood-pressure control, reduced the rate of progression of diabetic retinopathy.

Hypertension and diabetic retinopathy—what’s the story?

These reports in type 2 diabetes accord with previous observational studies in type 1 diabetes and demonstrate both hypertension as a risk factor for diabetic retinopathy and the beneficial effects of tight blood pressure control.